{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:21:27Z","timestamp":1761488487581},"reference-count":41,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            This open, randomized phase I study evaluated the safety and reactogenicity of an experimental meningococcal serogroup B (MenB) vaccine obtained from outer membrane vesicle detoxified L3-derived lipooligosaccharide. Healthy young adults (\n            <jats:italic>n<\/jats:italic>\n            = 150) were randomized to receive either experimental vaccine (provided in five formulations,\n            <jats:italic>n<\/jats:italic>\n            = 25 in each group) or VA-Mengoc-BC (control,\n            <jats:italic>n<\/jats:italic>\n            = 25) administered on a 0- to 6-week\/6-month schedule. Serum bactericidal assays performed against three MenB wild-type strains assessed the immune response, defined as a 4-fold increase from pre- to postvaccination. No serious adverse events related to vaccination were reported. Pain at the injection site, fatigue, and headache were the most commonly reported adverse events. Solicited adverse events graded level 3 (i.e., preventing daily activity) were pain (up to 17% of the test subjects versus 32% of the controls), fatigue (up to 12% of the test subjects versus 8% of the controls), and headache (up to 4% of any group). Swelling graded level 3 (greater than 50 mm) occurred in up to 4% of the test subjects versus 8% of the controls. The immune responses ranged from 5% to 36% across experimental vaccines for the L3 H44-76 strain (versus 27% for the control), from 0% to 11% for the L3 NZ98\/124 strain (versus 23% for the control), and from 0% to 13% for the L2 760676 strain (versus 59% for the control). All geometric mean titers were below those measured with the control vaccine. The five experimental formulations were safe and well tolerated but tended to be less immunogenic than the control vaccine.\n          <\/jats:p>","DOI":"10.1128\/cvi.00129-10","type":"journal-article","created":{"date-parts":[[2010,7,22]],"date-time":"2010-07-22T02:20:00Z","timestamp":1279765200000},"page":"1460-1466","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["Three Doses of an Experimental Detoxified L3-Derived Lipooligosaccharide Meningococcal Vaccine Offer Good Safety but Low Immunogenicity in Healthy Young Adults"],"prefix":"10.1128","volume":"17","author":[{"given":"Pablo","family":"Bonvehi\u0301","sequence":"first","affiliation":[{"name":"Centro de Educacio\u0301n Me\u0301dica e Investigaciones Cli\u0301nicas (CEMIC), Buenos Aires, Argentina"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"GSK Argentina, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Boutriau","sequence":"additional","affiliation":[{"name":"Centro de Educacio\u0301n Me\u0301dica e Investigaciones Cli\u0301nicas (CEMIC), Buenos Aires, Argentina"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"GSK Argentina, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Casellas","sequence":"additional","affiliation":[{"name":"Centro de Educacio\u0301n Me\u0301dica e Investigaciones Cli\u0301nicas (CEMIC), Buenos Aires, Argentina"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"GSK Argentina, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Weynants","sequence":"additional","affiliation":[{"name":"Centro de Educacio\u0301n Me\u0301dica e Investigaciones Cli\u0301nicas (CEMIC), Buenos Aires, Argentina"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"GSK Argentina, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Feron","sequence":"additional","affiliation":[{"name":"Centro de Educacio\u0301n Me\u0301dica e Investigaciones Cli\u0301nicas (CEMIC), Buenos Aires, Argentina"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"GSK Argentina, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Poolman","sequence":"additional","affiliation":[{"name":"Centro de Educacio\u0301n Me\u0301dica e Investigaciones Cli\u0301nicas (CEMIC), Buenos Aires, Argentina"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"GSK Argentina, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"970","volume":"12","year":"2005","unstructured":"Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. Hoiby, E. Rosenqvist, P. Balmer, and D. Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol.12:970-976.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00230-06"},{"key":"e_1_3_2_4_2","first-page":"575","volume":"98","year":"2007","unstructured":"Br\u00f6ker, M., and S. Fantoni. 2007. Meningococcal disease: a review on available vaccines and vaccines in development. Minerva Med.98:575-589.","journal-title":"Minerva Med."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","volume":"22","year":"2004","unstructured":"Bruge, J., C. N. Bouveret-Le, B. Danve, G. Rougon, and D. Schulz. 2004. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine22:1087-1096.","journal-title":"Vaccine"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.12968\/hosp.2002.63.5.2017","volume":"63","year":"2002","unstructured":"Cartwright, K. A. 2002. Epidemiology of meningococcal disease. Hosp. Med.63:264-267.","journal-title":"Hosp. Med."},{"key":"e_1_3_2_7_2","first-page":"21","volume":"39","year":"2007","unstructured":"Chi\u00e1vetta, L., E. Chavez, A. Ruzic, M. Mollerach, and M. Regueira. 2007. Surveillance of Neisseria meningitidis in Argentina, 1993-2005: distribution of serogroups, serotypes and serosubtypes isolated from invasive disease. Rev. Argent. Microbiol.39:21-27.","journal-title":"Rev. Argent. Microbiol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","volume":"340","year":"1992","unstructured":"de Moraes, J. C., B. A. Perkins, M. C. Camargo, N. T. Hidalgo, H. A. Barbosa, C. T. Sacchi, I. M. Landgraf, V. L. Gattas, H. D. Vasconcelos, et al. 1992. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet340:1074-1078.","journal-title":"Lancet"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1055\/s-2004-836094","volume":"129","year":"2004","unstructured":"Dittmann, S. 2004. Meningococcal disease. Dtsch. Med. Wochenschr.129:2666-2671.","journal-title":"Dtsch. Med. Wochenschr."},{"key":"e_1_3_2_10_2","unstructured":"Response to an outbreak of meningococcal disease due to a B:14:P1.7 16 strain 2007"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00466-06"},{"key":"e_1_3_2_12_2","first-page":"355","volume":"2","year":"1983","unstructured":"Finne, J., M. Leinonen, and P. H. M\u00e4kel\u00e4. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet2:355-357.","journal-title":"Lancet"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","year":"1969","unstructured":"Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med.129:1307-1326.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00118-09"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"B117","DOI":"10.1016\/j.vaccine.2009.04.066","volume":"27","year":"2009","unstructured":"Granoff, D. M. 2009. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine27(Suppl. 2):B117-B125.","journal-title":"Vaccine"},{"key":"e_1_3_2_16_2","first-page":"399","year":"2008","unstructured":"Granoff, D. M., L. H. Harrisson, and R. Borrow. 2008. Meningococcal vaccines, p. 399-434. In S. A. Plotkin, P. A. Offit, and W. A. Orenstein (ed.), Vaccines, 5th ed. W. B. Saunders Company, Philadelphia, PA.","journal-title":"Vaccines"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4161\/hv.4513","volume":"3","year":"2007","unstructured":"Holst, J. 2007. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum. Vaccin.3:290-294.","journal-title":"Hum. Vaccin."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.vaccine.2005.01.058","volume":"23","year":"2005","unstructured":"Holst, J., B. Fiering, L. M. Naess, G. Norheim, P. Kristiansen, E. A. Hoiby, K. Bryn, P. Oster, P. Costantino, M. K. Taha, J. M. Alonso, D. A. Caugant, E. Wedege, I. S. Aaberge, R. Rappuoli, and E. Rosenqvist. 2005. The concept of \u201ctailor-made,\u201d protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine23:2202-2205.","journal-title":"Vaccine"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00167-07"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0882-4010(92)90022-G","volume":"13","year":"1992","unstructured":"Jones, D. M., R. Borrow, A. J. Fox, S. Gray, K. A. Cartwright, and J. T. Poolman. 1992. The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb. Pathog.13:219-224.","journal-title":"Microb. Pathog."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.11.6503-6510.2004"},{"key":"e_1_3_2_22_2","first-page":"148","volume":"11","year":"2006","unstructured":"Levy-Bruhl, D. 2006. Is there a need for a public vaccine production capacity at European level? Euro Surveill.11:148-149.","journal-title":"Euro Surveill."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1016\/S0264-410X(01)00209-2","volume":"19","year":"2001","unstructured":"Lingappa, J. R., N. Rosenstein, E. R. Zell, K. A. Shutt, A. Schuchat, and B. A. Perkins. 2001. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine19:4566-4575.","journal-title":"Vaccine"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1084\/jem.168.1.107","volume":"168","year":"1988","unstructured":"Mandrell, R. E., J. M. Griffiss, and B. A. Macher. 1988. Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes. J. Exp. Med.168:107-126.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/ije\/24.5.1050","volume":"24","year":"1995","unstructured":"Noronha, C. P., C. J. Struchiner, and M. E. Halloran. 1995. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int. J. Epidemiol.24:1050-1057.","journal-title":"Int. J. Epidemiol."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","volume":"23","year":"2005","unstructured":"Oster, P., D. Lennon, J. O'Hallahan, K. Mulholland, S. Reid, and D. Martin. 2005. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine23:2191-2196.","journal-title":"Vaccine"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","volume":"177","year":"1998","unstructured":"Perkins, B. A., K. Jonsdottir, H. Briem, E. Griffiths, B. D. Plikaytis, E. A. Hoiby, E. Rosenqvist, J. Holst, H. Nokleby, F. Sotolongo, G. Sierra, H. C. Campa, G. M. Carlone, D. Williams, J. Dykes, D. Kapczynski, E. Tikhomirov, J. D. Wenger, and C. V. Broome. 1998. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis.177:683-691.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_28_2","first-page":"465","volume":"116","year":"1980","unstructured":"Poolman, J., C. Hopman, and H. Zanen. 1980. Immunochemical characterization of Neisseria meningitidis serotype antigens by immunodiffusion and SDS-polyacrylamide gel electrophoresis immunoperoxidase techniques and the distribution of serotypes among cases and carriers. J. Gen. Microbiol.116:465-473.","journal-title":"J. Gen. Microbiol."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/glycob\/11.8.703","volume":"11","year":"2001","unstructured":"Rahman, M. M., C. M. Kahler, D. S. Stephens, and R. W. Carlson. 2001. The structure of the lipooligosaccharide (LOS) from the alpha-1,2-N-acetyl glucosamine transferase (rfaKNMB) mutant strain CMK1 of Neisseria meningitidis: implications for LOS inner core assembly and LOS-based vaccines. Glycobiology11:703-709.","journal-title":"Glycobiology"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/mpat.1997.0143","volume":"23","year":"1997","unstructured":"Rune Andersen, S., J. Kolberg, E. A. Hoiby, E. Namork, D. A. Caugant, F. L. Oddvar, E. Jantzen, and G. Bjune. 1997. Lipopolysaccharide heterogeneity and escape mechanisms of Neisseria meningitidis: possible consequences for vaccine development. Microb. Pathog.23:139-155.","journal-title":"Microb. Pathog."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1099\/00222615-41-4-236","volume":"41","year":"1994","unstructured":"Scholten, R. J., B. Kuipers, H. A. Valkenburg, J. Dankert, W. D. Zollinger, and J. T. Poolman. 1994. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J. Med. Microbiol.41:236-243.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_32_2","first-page":"195","volume":"14","year":"1991","unstructured":"Sierra, G. V., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14:195-207.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00005-08"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4161\/hv.3.4.4174","volume":"3","year":"2007","unstructured":"Taha, M. K., and J. M. Alonso. 2007. Meningococcal vaccines: to eradicate the disease, not the bacterium. Hum. Vaccin.3:149-152.","journal-title":"Hum. Vaccin."},{"key":"e_1_3_2_35_2","first-page":"1520","volume":"281","year":"1999","unstructured":"Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. Hoiby, J. Holst, H. Nokleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281:1520-1527.","journal-title":"JAMA"},{"key":"e_1_3_2_36_2","first-page":"33","volume":"5","year":"2003","unstructured":"Vermont, C. L., G. P. van den Dobbelsteen, and R. de Groot. 2003. Recent developments in vaccines to prevent meningococcal serogroup B infections. Curr. Opin. Mol. Ther.5:33-38.","journal-title":"Curr. Opin. Mol. Ther."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.4.1650-1655.2003"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00039-07"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00341-07"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01108-08"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00411-07"},{"key":"e_1_3_2_42_2","unstructured":"Multivalent group B meningococcal vaccine based on native outer membrane vesicles (NOMV) has potential for providing safe broadly protective immunity 2008"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00129-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00129-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:44:08Z","timestamp":1627591448000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00129-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1128\/CVI.00129-10"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00129-10","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"2010-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-07-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}